Avanir Deal Partly Plugs Otsuka’s Abilify Gap
This article was originally published in PharmAsia News
While some eyebrows are being raised over the sum Otsuka Pharmaceutical is proposing to shell out for a small U.S. CNS company with only one niche marketed product, the pipeline the deal will bring is being viewed positively by some analysts.
You may also be interested in...
Otsuka liked the private US antibody tech company Visterra so much that it is buying it, in a move developing out of licensing discussions and which the Japanese firm says will strengthen its presence in biologics for renal disorders and other high-need areas.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.